Berg DD, et al. - In a prospective biomarker study (n=8705) nested within a multinational randomized trial of the oral factor Xa inhibitor edoxaban in patients with atrial fibrillation and a CHADS2 score ≥2 (ENGAGE AF-TIMI 48- Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48), researchers tested ABC(age, biomarker, clinical history)-stroke [age, prior stroke/transient ischemic attack, hsTnT (high-sensitivity troponin T), NT-proBNP (N-terminal B-type natriuretic peptide)] and ABC-bleeding [age, prior bleeding, hemoglobin, hsTnT, and growth differentiation factor-15 (GDF-15)] scores and analyzed hsTnT, NT-proBNP, and GDF-15, at baseline and after 12 months. In this anticoagulated clinical trial cohort, the ABC-stroke and ABC-bleeding scores evaluated were well calibrated. Compared to CHA₂DS₂-VASc and HAS-BLED scores, the ABC-stroke and ABC-bleeding scores displayed better performance. Those who could be benefitted with non–vitamin K antagonist oral anticoagulants could be detected with the help of these scores.